Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

Ibrutinib, a clinically approved irreversible BTK kinase inhibitor for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) etc, has been reported to be potent against EGFR mutant kinase and currently being evaluated in clinic for Non Small Cell Lung Cancer (NSCLC). Through EGFR wt/muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Aoli, Yan, Xiao-E, Wu, Hong, Wang, Wenchao, Hu, Chen, Chen, Cheng, Zhao, Zheng, Zhao, Peng, Li, Xixiang, Wang, Li, Wang, Beilei, Ye, Zi, Wang, Jinhua, Wang, Chu, Zhang, Wei, Gray, Nathanael S., Weisberg, Ellen L., Chen, Liang, Liu, Jing, Yun, Cai-Hong, Liu, Qingsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342513/
https://www.ncbi.nlm.nih.gov/pubmed/27626175
http://dx.doi.org/10.18632/oncotarget.11951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342513/
https://www.ncbi.nlm.nih.gov/pubmed/27626175
http://dx.doi.org/10.18632/oncotarget.11951

Ejemplares similares